123 related articles for article (PubMed ID: 31560288)
1. Ellipticine, its Derivatives: Re-evaluation of Clinical Suitability with the Aid of Drug Delivery Systems.
Dan VM; Varghese TS; Viswanathan G; Baby S
Curr Cancer Drug Targets; 2020; 20(1):33-46. PubMed ID: 31560288
[TBL] [Abstract][Full Text] [Related]
2. Self-assembling peptide-based nanoparticles enhance cellular delivery of the hydrophobic anticancer drug ellipticine through caveolae-dependent endocytosis.
Bawa R; Fung SY; Shiozaki A; Yang H; Zheng G; Keshavjee S; Liu M
Nanomedicine; 2012 Jul; 8(5):647-54. PubMed ID: 21889478
[TBL] [Abstract][Full Text] [Related]
3. Self-assembling peptide-based nanoparticles enhance anticancer effect of ellipticine in vitro and in vivo.
Wu Y; Sadatmousavi P; Wang R; Lu S; Yuan YF; Chen P
Int J Nanomedicine; 2012; 7():3221-33. PubMed ID: 22802684
[TBL] [Abstract][Full Text] [Related]
4. Molecular binding of self-assembling peptide EAK16-II with anticancer agent EPT and its implication in cancer cell inhibition.
Lu S; Wang H; Sheng Y; Liu M; Chen P
J Control Release; 2012 May; 160(1):33-40. PubMed ID: 22465389
[TBL] [Abstract][Full Text] [Related]
5. Sequence effect of self-assembling peptides on the complexation and in vitro delivery of the hydrophobic anticancer drug ellipticine.
Fung SY; Yang H; Chen P
PLoS One; 2008 Apr; 3(4):e1956. PubMed ID: 18398476
[TBL] [Abstract][Full Text] [Related]
6. Encapsulation of Ellipticine in poly-(3-hydroxybutyrate-co-3-hydroxyvalerate) based nanoparticles and its in vitro application.
Masood F; Chen P; Yasin T; Fatima N; Hasan F; Hameed A
Mater Sci Eng C Mater Biol Appl; 2013 Apr; 33(3):1054-60. PubMed ID: 23827542
[TBL] [Abstract][Full Text] [Related]
7. Preparation of pH-responsive polymer core-shell nanospheres for delivery of hydrophobic antineoplastic drug ellipticine.
Wang H; Yang L; Rempel GL
Macromol Biosci; 2014 Feb; 14(2):166-72. PubMed ID: 24106137
[TBL] [Abstract][Full Text] [Related]
8. Formation of DNA adducts by ellipticine and its micellar form in rats - a comparative study.
Stiborova M; Manhartova Z; Hodek P; Adam V; Kizek R; Frei E
Sensors (Basel); 2014 Dec; 14(12):22982-97. PubMed ID: 25479328
[TBL] [Abstract][Full Text] [Related]
9. Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine.
Liu J; Xiao Y; Allen C
J Pharm Sci; 2004 Jan; 93(1):132-43. PubMed ID: 14648643
[TBL] [Abstract][Full Text] [Related]
10. Influence of serum protein on polycarbonate-based copolymer micelles as a delivery system for a hydrophobic anti-cancer agent.
Liu J; Zeng F; Allen C
J Control Release; 2005 Mar; 103(2):481-97. PubMed ID: 15763628
[TBL] [Abstract][Full Text] [Related]
11. Ellipticine-loaded apoferritin nanocarrier retains DNA adduct-based cytochrome P450-facilitated toxicity in neuroblastoma cells.
Indra R; Černá T; Heger Z; Hraběta J; Wilhelm M; Dostálová S; Lengálová A; Martínková M; Adam V; Eckschlager T; Schmeiser HH; Arlt VM; Stiborová M
Toxicology; 2019 May; 419():40-54. PubMed ID: 30914192
[TBL] [Abstract][Full Text] [Related]
12. Multi-responsive polymer micelles as ellipticine delivery carriers for cancer therapy.
Studenovský M; Sedláček O; Hrubý M; Pánek J; Ulbrich K
Anticancer Res; 2015 Feb; 35(2):753-7. PubMed ID: 25667454
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of peptide mediated delivery of anticancer drug ellipticine.
Ma W; Lu S; Pan P; Sadatmousavi P; Yuan Y; Chen P
PLoS One; 2012; 7(8):e43684. PubMed ID: 22952737
[TBL] [Abstract][Full Text] [Related]
14. Ellipticines as DNA-targeted chemotherapeutics.
Stiborová M; Frei E
Curr Med Chem; 2014; 21(5):575-91. PubMed ID: 24059226
[TBL] [Abstract][Full Text] [Related]
15. Bioactivities and Action Mechanisms of Ellipticine Derivatives Reported Prior to 2023.
Hou W; Xu XL; Huang LJ; Zhang ZY; Zhou ZN; Wang JY; Ouyang X; Xin SY; Zhang ZY; Xiong Y; Huang H; Lan JX
Chem Biodivers; 2024 May; 21(5):e202400210. PubMed ID: 38433548
[TBL] [Abstract][Full Text] [Related]
16. Extending nature's leads: the anticancer agent ellipticine.
Garbett NC; Graves DE
Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):149-72. PubMed ID: 15032720
[TBL] [Abstract][Full Text] [Related]
17. Excited state proton transfer dynamics of an eminent anticancer drug, ellipticine, in octyl glucoside micelle.
Gavvala K; Koninti RK; Sengupta A; Hazra P
Phys Chem Chem Phys; 2014 Jul; 16(28):14953-60. PubMed ID: 24931633
[TBL] [Abstract][Full Text] [Related]
18. Thermotropic phase behavior of DPPC liposome systems in the presence of the anti-cancer agent 'Ellipticine'.
Cavalcanti LP; Torriani IL
Eur Biophys J; 2006 Dec; 36(1):67-71. PubMed ID: 16794849
[TBL] [Abstract][Full Text] [Related]
19. Antiplasmodial activity of synthetic ellipticine derivatives and an isolated analog.
Montoia A; Rocha E Silva LF; Torres ZE; Costa DS; Henrique MC; Lima ES; Vasconcellos MC; Souza RC; Costa MR; Grafov A; Grafova I; Eberlin MN; Tadei WP; Amorim RC; Pohlit AM
Bioorg Med Chem Lett; 2014 Jun; 24(12):2631-4. PubMed ID: 24813729
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells.
Martinkova E; Dontenwill M; Frei E; Stiborova M
Neuro Endocrinol Lett; 2009; 30 Suppl 1():60-6. PubMed ID: 20027146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
